190 related articles for article (PubMed ID: 34283890)
1. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.
Rais R; Trikalinos NA; Liu J; Chatterjee D
Arch Pathol Lab Med; 2022 Mar; 146(3):366-371. PubMed ID: 34283890
[TBL] [Abstract][Full Text] [Related]
2. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
3. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
McCarthy DM
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
[TBL] [Abstract][Full Text] [Related]
4. The Morphologic Spectrum of Gastric Type 1 Enterochromaffin-Like Cell Neuroendocrine Tumors.
Poveda JC; Chahar S; Garcia-Buitrago MT; Montgomery EA; McDonald OG
Mod Pathol; 2023 Apr; 36(4):100098. PubMed ID: 36913909
[TBL] [Abstract][Full Text] [Related]
5. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
6. Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa.
Tatsuguchi A; Hoshino S; Kawami N; Gudis K; Nomura T; Shimizu A; Iwakiri K
Pathol Res Pract; 2020 Oct; 216(10):153113. PubMed ID: 32853950
[TBL] [Abstract][Full Text] [Related]
7. Gastric neuroendocrine tumours from long-term proton pump inhibitor users are indolent tumours with good prognosis.
Trinh VQ; Shi C; Ma C
Histopathology; 2020 Dec; 77(6):865-876. PubMed ID: 32702178
[TBL] [Abstract][Full Text] [Related]
8. Gastric carcinoids after long-term use of a proton pump inhibitor.
Jianu CS; Fossmark R; Viset T; Qvigstad G; Sørdal O; Mårvik R; Waldum HL
Aliment Pharmacol Ther; 2012 Oct; 36(7):644-9. PubMed ID: 22861200
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
10. Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?
Waldum HL; Hauso Ø; Brenna E; Qvigstad G; Fossmark R
Scand J Gastroenterol; 2016 Jul; 51(7):767-73. PubMed ID: 26872579
[TBL] [Abstract][Full Text] [Related]
11. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
12. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
[TBL] [Abstract][Full Text] [Related]
13. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas.
Peghini PL; Annibale B; Azzoni C; Milione M; Corleto VD; Gibril F; Venzon DJ; Delle Fave G; Bordi C; Jensen RT
Gastroenterology; 2002 Jul; 123(1):68-85. PubMed ID: 12105835
[TBL] [Abstract][Full Text] [Related]
15. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence?
Cavalcoli F; Zilli A; Conte D; Ciafardini C; Massironi S
Scand J Gastroenterol; 2015; 50(11):1397-403. PubMed ID: 26059834
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of ECL-cell abnormalities.
Hirschowitz BI
Yale J Biol Med; 1998; 71(3-4):303-10. PubMed ID: 10461361
[TBL] [Abstract][Full Text] [Related]
17. [Study on histogenesis of enterochromaffin-like carcinoid in autoimmune atrophic gastritis associated with pernicious anemia].
Macukanović-Golubović L; Katić V; Rancić G; Milenović M; Marjanović G; Golubović Z
Vojnosanit Pregl; 2007 Aug; 64(8):543-8. PubMed ID: 17874722
[TBL] [Abstract][Full Text] [Related]
18. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
[TBL] [Abstract][Full Text] [Related]
19. Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.
Li TT; Qiu F; Qian ZR; Wan J; Qi XK; Wu BY
World J Gastroenterol; 2014 Jan; 20(1):118-25. PubMed ID: 24415864
[TBL] [Abstract][Full Text] [Related]
20. Hypergastrinemia and gastric enterochromaffin-like cells.
Bordi C; D'Adda T; Azzoni C; Pilato FP; Caruana P
Am J Surg Pathol; 1995; 19 Suppl 1():S8-19. PubMed ID: 7762739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
